Louis Elan D, Factor-Litvak Pam, Michalec Monika, Jiang Wendy, Zheng Wei
GH Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Neurotoxicology. 2014 Sep;44:110-3. doi: 10.1016/j.neuro.2014.06.010. Epub 2014 Jun 23.
Harmane (1-methyl-9H-pyrido[3,4-b]indole) (HA) is a potent neurotoxin that has been linked to two neurological diseases, essential tremor and Parkinson's disease. Blood harmane concentrations [HA] are elevated in patients with both diseases. An important question is whether HA is specifically linked with these diseases or alternatively, is a non-specific marker of neurological illness.
We assessed whether blood [HA] was elevated in patients with a third neurological disease, dystonia, comparing them to controls.
Blood [HA] was quantified by high performance liquid chromatography. Subjects comprised 104 dystonia cases and 107 controls.
Mean log blood [HA] in dystonia cases was similar to that of controls (0.41±0.51g(-10)/ml vs. 0.38±0.61g(-10)/ml, t=0.42, p=0.68). In unadjusted and adjusted logistic regression analyses, log blood [HA] was not associated with the outcome (diagnosis of dystonia vs. control): odds ratio (OR)unadjusted=1.11, 95% confidence interval (CI)=0.69-1.79, p=0.68; ORadjusted=1.07, 95% CI=0.58-1.97, p=0.84.
In contrast to the elevated blood [HA] that has been reported in patients with essential tremor and Parkinson's disease, our data demonstrate that blood [HA] was similar in patients with dystonia and controls. These findings provide the first support for the notion that an elevated blood [HA] is not a broad feature of neurological disease, and may be a specific feature of certain tremor disorders.
哈尔满（1-甲基-9H-吡啶并[3,4-b]吲哚）（HA）是一种强效神经毒素，与两种神经系统疾病——特发性震颤和帕金森病有关。这两种疾病患者的血液哈尔满浓度[HA]均会升高。一个重要的问题是，HA是与这些疾病有特异性关联，还是仅仅是神经系统疾病的非特异性标志物。
我们评估了第三种神经系统疾病——肌张力障碍患者的血液[HA]是否升高，并将他们与对照组进行比较。
采用高效液相色谱法定量血液[HA]。研究对象包括104例肌张力障碍患者和107名对照者。
肌张力障碍患者的平均血液[HA]对数与对照组相似（0.41±0.51g(-10)/ml对0.38±0.61g(-10)/ml，t=0.42，p=0.68）。在未校正和校正后的逻辑回归分析中，血液[HA]对数与结局（肌张力障碍诊断与对照）无关：未校正比值比（OR）=1.11，95%置信区间（CI）=0.69-1.79，p=0.68；校正后OR=1.07，95%CI=0.58-1.97，p=0.84。
与特发性震颤和帕金森病患者血液[HA]升高的报道不同，我们的数据表明，肌张力障碍患者和对照组的血液[HA]相似。这些发现首次支持了血液[HA]升高并非神经系统疾病普遍特征，而可能是某些震颤性疾病特异性特征的观点。
